Literature DB >> 8663292

Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro.

J D Medh1, S L Bowen, G L Fry, S Ruben, M Andracki, I Inoue, J M Lalouel, D K Strickland, D A Chappell.   

Abstract

Lipoprotein lipase (LPL), the major enzyme responsible for the hydrolysis of plasma triglycerides, promotes binding and catabolism of triglyceride-rich lipoproteins by various cultured cells. Recent studies demonstrate that LPL binds to three members of the low density lipoprotein (LDL) receptor family, including the LDL receptor-related protein (LRP), GP330/LRP-2, and very low density lipoprotein (VLDL) receptors and induces receptor-mediated lipoprotein catabolism. We show here that LDL receptors also bind LPL and mediate LPL-dependent catabolism of large VLDL with Sf 100-400. Up-regulation of LDL receptors by lovastatin treatment of normal human foreskin fibroblasts (FSF cells) resulted in an increase in LPL-induced VLDL binding and catabolism to a level that was 10-15-fold greater than in LDL receptor-negative fibroblasts, despite similar LRP activity in both cell lines. This indicates that the contribution of LRP to LPL-dependent degradation of VLDL is small when LDL receptors are maximally up-regulated. Furthermore studies in LRP-deficient murine embryonic fibroblasts showed that the level of LPL-dependent degradation of VLDL was similar to that in normal murine embryonic fibroblasts. LPL also promoted the internalization of protein-free triglyceride emulsions; lovastatin-treatment resulted in 2-fold higher uptake in FSF cells, indicating that LPL itself could bind to LDL receptors. However, the lower induction of emulsion catabolism as compared with native VLDL suggests that LPL-induced catabolism via LDL receptors is only partially dependent on receptor binding by LPL and instead is primarily due to activation of apolipoproteins such as apoE. A fusion protein between glutathione S-transferase and the catalytically inactive carboxyl-terminal domain of LPL (GST-LPLC) also induced binding and catabolism of VLDL. However GST-LPLC was not as active as native LPL, indicating that lipolysis is required for a maximal LPL effect. Mutations of critical tryptophan residues in GST-LPLC that abolished binding to VLDL converted the protein to an inhibitor of lipoprotein binding to LDL receptors. In solid-phase assays using immobilized receptors, LDL receptors bound to LPL in a dose-dependent manner. Both LPL and GST-LPLC promoted binding of VLDL to LDL receptor-coated wells. These results indicate that LPL binds to LDL receptors and suggest that the carboxyl-terminal domain of LPL contributes to this interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663292     DOI: 10.1074/jbc.271.29.17073

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

Authors:  P J Tacken; F D Beer; L C Vark; L M Havekes; M H Hofker
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

2.  Very low density lipoproteins stimulate surfactant lipid synthesis in vitro.

Authors:  R K Mallampalli; R G Salome; S L Bowen; D A Chappell
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

3.  Not the mature 56 kDa lipoprotein lipase protein but a 37 kDa protein co-purifying with the lipase mediates the binding of low density lipoproteins to J774 macrophages.

Authors:  W L Hendriks; L C Van Vark; K Schoonderwoerd; H Jansen; L M Havekes
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 4.  Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

Authors:  Vassilis I Zannis; Angeliki Chroni; Monty Krieger
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

5.  Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Authors:  Alexander M Vezeridis; Konstantinos Drosatos; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

Review 6.  Lipoprotein lipase in the brain and nervous system.

Authors:  Hong Wang; Robert H Eckel
Journal:  Annu Rev Nutr       Date:  2012-04-23       Impact factor: 11.848

7.  Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.

Authors:  J D Medh; G L Fry; S L Bowen; S Ruben; H Wong; D A Chappell
Journal:  J Lipid Res       Date:  2000-11       Impact factor: 5.922

8.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

9.  Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation.

Authors:  M Rudling; M Gåfvels; P Parini; G Gahrton; B Angelin
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Species-specific receptor recognition by a minor-group human rhinovirus (HRV): HRV serotype 1A distinguishes between the murine and the human low-density lipoprotein receptor.

Authors:  Manuela Reithmayer; Andrea Reischl; Luc Snyers; Dieter Blaas
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.